STIFEL FINANCIAL CORP - RHYTHM PHARMACEUTICALS INC ownership

RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 147 filers reported holding RHYTHM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.

Quarter-by-quarter ownership
STIFEL FINANCIAL CORP ownership history of RHYTHM PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$1,054,335
+36.9%
45,990
-1.5%
0.00%0.0%
Q2 2023$770,022
+100.8%
46,696
+117.3%
0.00%0.0%
Q1 2023$383,382
-32.1%
21,490
+10.9%
0.00%0.0%
Q4 2022$564,345
+17.6%
19,380
-1.0%
0.00%0.0%
Q3 2022$480,000
+507.6%
19,580
+3.3%
0.00%
Q2 2022$79,000
-73.9%
18,961
-28.1%
0.00%
Q1 2022$303,000
-58.9%
26,366
-64.3%
0.00%
-100.0%
Q4 2021$738,000
-58.0%
73,913
-45.1%
0.00%
-66.7%
Q3 2021$1,757,000
-50.5%
134,586
-25.8%
0.00%
-40.0%
Q2 2021$3,552,000
+42.5%
181,414
+54.7%
0.01%
+25.0%
Q1 2021$2,493,000
+618.4%
117,233
+905.9%
0.00%
+300.0%
Q4 2020$347,000
+30.5%
11,654
+36.5%
0.00%0.0%
Q2 2018$266,0008,5380.00%
Other shareholders
RHYTHM PHARMACEUTICALS INC shareholders Q3 2023
NameSharesValueWeighting ↓
COMMODORE CAPITAL LP 2,075,000$47,569,3755.56%
NEA Management Company, LLC 2,909,956$66,710,7415.15%
Opaleye Management Inc. 653,000$14,970,0254.87%
Frazier Life Sciences Management, L.P. 2,371,304$54,362,1443.61%
VR Adviser, LLC 1,090,000$24,988,2502.63%
RA Capital Management 5,676,067$130,123,8362.56%
Samsara BioCapital, LLC 345,293$7,915,8422.42%
SILVERARC CAPITAL MANAGEMENT, LLC 260,537$5,972,8111.81%
Logos Global Management LP 400,000$9,170,0001.22%
Cormorant Asset Management, LP 850,000$19,486,2501.14%
View complete list of RHYTHM PHARMACEUTICALS INC shareholders